Trending AI and Digital Solutions in Radiology—current adoption, applications and continuing developments

• 举报此文章

Meximp Technologies

Meximp Technologies

发布日期: 2021年9月21日

+ 关注

In the wake of the global COVID-19 pandemic, the use of artificial intelligence (AI) in healthcare is on the rise. Progress in anything seemed to be held static while leaders and healthcare providers focused on stopping the spread of COVID-19 and treating infected patients, but the opposite was true in AI. Read more

要查看或添加评论，请登录

Meximp Technologies的更多文章

• Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye

  2023年5月5日

  Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye

  Agilent Technologies Inc. (NYSE: A) announced today that Dr.

  3

  1 条评论
• Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  2022年10月21日

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx…

  2
• Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

  2022年7月26日

  Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

  Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a…

  1
• Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

  2022年4月7日

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

  Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1…

  4
• Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  2022年4月7日

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx…

  1
• The Innovators 2021

  2022年1月21日

  The Innovators 2021

  R-TRACKER: A TRUE MILESTONE IN SPECIMEN TRACEABILITY Traceability is of paramount importance for patient safety – this…

  4
• Agilent Names John Palma to Lead Global Medical Affairs Organization

  2021年11月9日

  Agilent Names John Palma to Lead Global Medical Affairs Organization

  Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Technologies, Inc. (NYSE: A) today…

• Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or E

  2021年10月22日

  Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or E

  Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric…

  1
• Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

  2021年10月22日

  Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

  Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an…

  1
• GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases

  2021年10月4日

  GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases

  GE Healthcare is proud to unveil MyoSPECT[ii], a next-generation cardiac-dedicated nuclear medicine scanner with…

Show more

See all articles